Related Experiment Videos
ZD6126: a novel small molecule vascular targeting agent
David C Blakey1, Susan E Ashton, F Russell Westwood
1Department of Cancer and Infection Bioscience, AstraZeneca, Alderley Park, England, Macclesfield, UK. david.blakey@astrazeneca.com
International Journal of Radiation Oncology, Biology, Physics
|December 3, 2002
Summary
The novel vascular targeting agent ZD6126 rapidly alters endothelial cell shape and causes tumor necrosis. Its rapid elimination and non-cytotoxic effects contribute to selective tumor vasculature targeting at well-tolerated doses.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Vascular targeting agents (VTAs) offer a promising strategy in cancer therapy by selectively damaging tumor vasculature.
- ZD6126 is a novel VTA designed to exploit differences between tumor and normal vasculature.
Purpose of the Study:
- To investigate the mechanisms underlying the selectivity of ZD6126.
- To evaluate the in vitro and in vivo effects of ZD6126 on endothelial cells and tumor growth.
Main Methods:
- Human umbilical vein endothelial cells (HUVECs) were treated with ZD6126 phenol to assess morphology, detachment, and cytotoxicity.
- Hras5-transformed mouse fibroblasts were implanted in rats, and tumor responses to ZD6126 administered via intravenous bolus or continuous infusion were evaluated.
Main Results:
- ZD6126 phenol rapidly destabilized the endothelial cell cytoskeleton at non-cytotoxic concentrations, causing cell rounding and detachment.
- Intravenous bolus administration of ZD6126 resulted in rapid breakdown to ZD6126 phenol with a short half-life, leading to extensive tumor necrosis.
- Continuous infusion of ZD6126 showed decreased efficacy and increased toxicity compared to bolus administration.
Conclusions:
- ZD6126 phenol induces rapid, non-cytotoxic morphologic changes in endothelial cells.
- The rapid elimination of ZD6126 phenol and its rapid morphologic effects contribute to ZD6126's selective action on tumor vasculature.
- ZD6126 demonstrates potential as a selective vascular targeting agent in cancer therapy.